Valuation: Galapagos NV

Market Cap 1.71B 1.96B 1.61B 1.47B 2.76B 187B 2.76B 19.32B 7.46B 95.69B 7.36B 7.2B 308B P/E 2026 *
-13.9x
P/E 2027 * -5.66x
Enterprise Value -718M -821M -674M -615M -1.16B -78.49B -1.16B -8.09B -3.12B -40.09B -3.08B -3.02B -129B EV / Sales 2026 *
-6.12x
EV / Sales 2027 * 2.37x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 2025-05-11
Director of Finance/CFO 41 2025-07-06
Chief Operating Officer - 2026-05-31
Director TitleAgeSince
Director/Board Member 63 2019-10-21
Director/Board Member 49 2024-10-06
Director/Board Member 53 2025-05-11
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 1.96B
-0.21%+4.20%+4.08%+29.83% 47.86B
+0.54%+1.17%+45.87%+34.38% 44.46B
-1.06%+4.55%+10.59%+91.15% 41.85B
-0.14%-1.75%+335.45%+552.51% 41.34B
-0.62%-0.06%+10.15%+46.02% 30.04B
-0.02%+2.58%+27.45%+158.42% 17.59B
-3.58%-7.31% - - 15.6B
-3.39%+2.12%+22.17%+39.35% 15.69B
-0.42%+9.83%-8.65% - 13.93B
Average -0.88%+2.66%+55.89%+135.95% 29.82B
Weighted average by Cap. -0.62%+1.88%+69.47%+144.02%

Financials

2026 *2027 *
Net sales 117M 134M 110M 101M 189M 12.82B 189M 1.32B 510M 6.55B 504M 493M 21.11B 84.62M 96.83M 79.53M 72.58M 136M 9.26B 136M 954M 368M 4.73B 364M 356M 15.24B
Net income -40.7M -46.57M -38.25M -34.9M -65.51M -4.45B -65.52M -459M -177M -2.27B -175M -171M -7.33B -213M -243M -200M -182M -342M -23.27B -342M -2.4B -926M -11.88B -914M -894M -38.31B
Net Debt -2.43B -2.78B -2.28B -2.08B -3.91B -266B -3.91B -27.42B -10.58B -136B -10.44B -10.22B -438B -1.51B -1.73B -1.42B -1.3B -2.43B -165B -2.43B -17.06B -6.58B -84.48B -6.5B -6.36B -272B
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!